Benefits
DashboardNot registered yet? Get a free account.
Sign UpNot registered yet? Get a free account.
Sign Up
You're about to leave our website and go to an external link. Are you sure?
Gland Pharma Ltd, is a listed public company incorporated on 20 March, 1978. It is classified as a public limited company and is located in Rangareddi, Telangana. It's authorized share capital is INR 56.30 cr and the total paid-up capital is INR 16.48 cr.
Gland Pharma Ltd's operating revenue range is Over INR 500 cr for the financial year ending on 31 March, 2022. It's EBITDA has increased by 16.0% over the previous year. At the same time, it's book networth has increased by 21.26%.
Read more
Buy Dashboard using Credits
This action will use 1 of your credits. Are you sure you want to go ahead?
Credits Balance:
0
** All rupee values in INR crores. Based on March 2022 numbers.
27.08%
16.0%
21.58%
21.26%
-0.03%
20.6%
-4.85
-3.28
-1.5
0.04
-0.26
Buy Report or Plans
Company dashboard
Five year financials and ratios
Risk analysis
Interactive charts
All financials
All annual returns
MoA and AoA
Latest financials
Latest annual return
MoA and AoA
Five year financials and ratios
Shareholding and group structure
Litigation and more
Everything in financial report
Peers and financials
* GST not included
** Reports & MCA filings will be based on the latest available financials.
India
(28)
| State | Type | Address |
|---|
Locations on Map
Filter (4)
Severe Risk
Moderate Risk
Low Risk
Read more
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Liquidity + | |||||
| Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Performance | |||||
| Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return + | |||||
| Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Efficiency + | |||||
| Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital | |||||
| Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Director | Naina Lal Kidwai | 00017806 | 4 years |
| Director | Satyanarayana Murthy Chavali | 00142138 | 6 years |
| Director | Essaji Goolam Vahanvati | 00157299 | 4 years |
| Director | Udo Jahannes Vetter | 00707474 | 7 years |
| CEO | Srinivas Sadu
Shareholder
|
<HIDDEN> | 6 years |
| Managing Director | Srinivas Sadu
Shareholder
|
06900659 | 0 years |
| Director | Jia Ai Zhang | 09170927 | 4 years |
| Director | Wenjie Zhang | 10727581 | 0 years |
| CS | Sampath Kumar Pallerlamudi | <HIDDEN> | 11 years |
| CFO | Ravi Shekhar Mitra | <HIDDEN> | 5 years |
| Name | Status | Paid up Capital | Common Directors | Address |
|---|---|---|---|---|
| NAYARA ENERGY LIMITED |
Active
|
1,490.6 Cr | 1 | Gujarat |
| ROTHSCHILD & CO INDIA PRIVATE LIMITED |
Active
|
13.5 Cr | 1 | Maharashtra |
| BIOCON LIMITED |
Active
|
600.3 Cr | 1 | Karnataka |
| UPL LIMITED |
Active
|
150.1 Cr | 1 | Gujarat |
| SATYARX PHARMA INNOVATIONS LLP |
Converted to CMP and Dissolved
|
1.0 Cr | 1 | Telangana |
| SATYATX PHARMA SERVICES LLP |
Active
|
1.0 L | 1 | Telangana |
| VIJAYA DIAGNOSTIC CENTRE LIMITED |
Active
|
10.3 Cr | 1 | Telangana |
| SATYARX PHARMA INNOVATIONS PRIVATE LIMITED |
Active
|
9.9 Cr | 1 | Telangana |
| JBM SOFTWARE DEVELOPMENT PRIVATE LIMITED |
Strike Off
|
1.0 L | 1 | Maharashtra |
| LENIENT FINVEST PRIVATE LIMITED |
Amalgamated
|
4.8 Cr | 1 | Maharashtra |
| SAFARI MERCANTILE PRIVATE LIMITED |
Amalgamated
|
4.8 Cr | 1 | Maharashtra |
| LUXURY LINK INDIA PRIVATE LIMITED |
Amalgamated
|
10.0 L | 1 | Maharashtra |
| AUGUSTA CONSULTANTS AND ADVISORS PRIVATE LIMITED |
Active
|
1.0 Cr | 1 | Maharashtra |
| DR. GOOLAM E VAHANVATI FOUNDATION |
Active
|
1.0 L | 1 | Maharashtra |
| MOORI EATERY PRIVATE LIMITED |
Active
|
1.0 L | 1 | Maharashtra |
| AGB OILS LLP |
Active
|
4.0 L | 1 | Maharashtra |
| BAGH TOLA JUNGLE LODGES LLP |
Active
|
25,000.0 | 1 | Maharashtra |
| R & V LEGAL ADVISORS LLP |
Active
|
50,000.0 | 1 | Maharashtra |
| ELCID INVESTMENTS LIMITED |
Active
|
20.0 L | 1 | Maharashtra |
| PASCHAL TECHNOLOGY (INDIA) PRIVATE LIMIT ED |
Amalgamated
|
2.1 Cr | 1 | Telangana |
| PASCHAL FORM WORK (INDIA) PRIVATE LIMITED |
Active
|
31.1 Cr | 1 | Andhra Pradesh |
| SADU ADVISORY SERVICES PRIVATE LIMITED |
Active
|
1.0 L | 1 | Telangana |
The incorporation date of GLAND PHARMA LTD is 20 March, 1978
The authorized share capital of GLAND PHARMA LTD is INR ₹ 56.3 Cr.
The paid-up capital of GLAND PHARMA LTD is INR ₹ 16.5 Cr.
The registered address of GLAND PHARMA LTD is SY.NO.143-148,150 &151,NEAR GANDI MAISAMMA X ROADS D.P.PAL LY,DUNDIGAL, DUNDIGAL - GANDIMAIS AMMA(M) MEDCHAL MALKAJGIRI DISTRICT HYDERABAD Rangareddi Telangana - 500043
The CIN number of GLAND PHARMA LTD is L24239TG1978PLC002276.
Expand
Delete
Collapse
See
details
It will take sometime. Please come back in 10
minutes
